Steering improved outcomes in non-driver mutation lung cancer:
progress and challenges

Chaired by Mark A. Socinski

IASLC 19th World Conference on Lung Cancer
Industry Supported Symposium

Metro Convention Centre North Building
Sunday 23rd September, 2018
13:00-14:30 in Room 106
Lunch will be provided

With Keith Kerr, Penelope Bradbury, James Yang, and Corey Langer


    Faculty interviews
    Click here to watch the expert’s summarise take home  messages from the symposium

    Scientific Summary

    The meeting report is available to download

    Complete the quiz at the end of this summary to earn 0.75 AMA PRA Category 1 CreditsTM


    13:00 Welcome and introduction

    Mark A. Socinski

    13:05 Histological and molecular profiling
    Keith Kerr

    13:20 Optimal sequencing of therapy for non-driver lung cancer: chemotherapy and immunotherapy
    Penelope Bradbury

    13:40 Optimal sequencing of therapy for non-driver lung cancer: chemotherapy and anti-angiogenics
    James Yang

    14:00 Identifying and treating patients with refractory or aggressive lung cancer
    Corey Langer

    14:20 Faculty discussion and audience questions



    This programme was approved by the IASLC 19th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 19th World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC.


    Following attendance at this symposium delegates are expected to:


    • Describe how the histological and molecular profiling may help to individualise
      care in nonsquamous and squamous NSCLC from the first-line setting through
      subsequent lines of treatment
    • Appraise data from the on-going trials in the field of non-driver lung cancer and
      understand how they can maximise patient outcomes
    • Debate the optimal sequencing and the pros and cons of the different available
      therapies for lung cancer patients without an actionable oncogenic driver
    • Identify patients with refractory and/or aggressive disease and explain how to optimally
      sequence treatment for these patients in daily clinical practice
  • Dear Colleagues,

    Welcome to the beautiful city of Toronto and thank you for joining us at ‘Steering improved outcomes in non-driver mutation lung cancer: progress and challenges’, an independent satellite symposium at the IASLC 19th World Conference on Lung Cancer.

    The IASLC World Conference on Lung Cancer is a world-renowned platform for the presentation and discussion of new science in the field of lung cancer and thoracic oncology. It is also the largest international meeting of clinicians, researchers and scientists in this field providing an ideal opportunity to learn about the latest research and network with colleagues from all over the world.

    This symposium aims to discuss the latest in non-driver mutation lung cancer, from histological and molecular profiling through to current and emerging treatment options, including for patients with refractory and aggressive disease. Our objective is to discuss the challenges that this patient group present and the progress being made to overcome them.

    Following the symposium we hope that your knowledge and understanding of this area will be enhanced and that you can utilise the learning in your daily practice. Our intention is to make the session as interactive as possible and you will have a chance to express your opinion on diagnosis and treatment decisions as well as put questions to the faculty of  international experts.

    We would be grateful if you could provide your feedback by completing the evaluation form provided.

    Many thanks and enjoy the meeting!

    Mark A Socinski – Chair

  • Mark A Socinski

    Florida Hospital Cancer Institute, USA

    Read full bio...

    Mark A Socinski is the Executive Medical Director of the Florida Hospital Cancer Institute in Orlando, FL. He received his medical degree from the University of Vermont, College of Medicine, and he completed his postdoctoral training including an internship and residency in internal medicine at the Beth Israel Hospital, and medical oncology fellowship at the Dana-Farber Cancer Institute, both at Harvard Medical School.

    Dr Socinski has held posts as Director of the Lung Cancer Section at the University of Pittsburgh Medical Center, Clinical Associate Director of the University of Pittsburgh Lung Cancer Specialized Program of Research Excellence (SPORE), Co-Director of UPMC Lung Cancer Center of Excellence, and Co-Leader of the Lung Cancer Program at the University of Pittsburgh Cancer Institute.

    He is a member of numerous professional societies, such as the American College of Physicians (ACP), American Society of Clinical Oncology (ASCO), Cancer and Leukemia Group B (Alliance), International Association for the Study of Lung Cancer (IASLC), and American College of Chest Physicians. Dr Socinski is also co-Chair Emeritus of the Thoracic Malignancies Steering Committee for the National Cancer Institute.

    Dr Socinski is well-published in peer-reviewed literature, including the New England Journal of Medicine, Journal of Clinical Oncology, Journal of Thoracic Oncology, Cancer, and The Lancet Oncology. His primary research interests cover all aspects of clinical trials related to the thoracic oncology population. He also has been instrumental in the development of many cooperative group and investigator-initiated clinical trials.


    Prof Keith Kerr

    Aberdeen University Medical School, UK

    Read full bio...

    Keith Kerr is a Consultant Pathologist for NHS Grampian and Honorary Chair in Pulmonary Pathology at the University of Aberdeen in Scotland. He has been an active member of IASLC for over 20 years, is a member and Chair-Elect of the IASLC Pathology Panel and served on the IASLC Board of Directors from 2013 to 2017.

    In 2016, he received the IASLC Mary Matthews award for Pathology and Translational Research. He is a member of European Society for Medical Oncology (ESMO), which includes serving on the ESMO Lung Educational Faculty. He is Pathology Chair for the European Thoracic Oncology Platform (ETOP) Lungscape group, and a past member of the panel for the 2004 and 2015 World Health Organization (WHO) lung cancer classifications.

    Professor Kerr has worked on numerous clinical research lung cancer trial groups, guideline panels, and conference scientific committees. He is an Associate Editor for the Journal of Thoracic Oncology. He received Honorary Fellowship from the Royal College of Physicians of Edinburgh in 2006 and has been an Honorary Fellow of the Faculty of Pathology, Royal College of Physicians of Ireland since 2016.


    Dr Penelope Bradbury

    Princess Margaret Cancer Centre, Toronto, ON, Canada

    Read full bio...

    Penelope Bradbury is Staff Medical Oncologist at the Princess Margaret Cancer Centre, Toronto, Canada; Associate Professor, Department of Medicine, University of Toronto, and adjunct Associate Professor within the Department of Oncology at Queen’s University, Kingston, Canada. After obtaining her medical degree from the University of Cardiff, UK, and a fellowship from the Australasian College of Physicians, she undertook postgraduate fellowships at Princess Margaret Cancer Centre and the Canadian Cancer Trials Group, in Ontario, Canada.

    She was previously a Senior Investigator in the Canadian Cancer Trials Group for the thoracic and investigational new drugs programme, during which she was Cancer Care Ontario Research Chair in Experimental Therapeutics. Dr Bradbury’s research interests include the evaluation of new therapies for the management of thoracic malignancies and clinical trial methodology. She is the current Chair of the Canadian Cancer Trials Group Thoracic Disease Site Committee.


    Dr James Yang

    National Taiwan University, Taipei City, Taiwan

    Read full bio...

    James Chih-Hsin Yang received his MD in 1986 from the National Taiwan University (NTU) and completed his PhD degree at the Graduate Institute of Clinical Medicine, NTU, in 2000. His first internal medicine residency was at the NTU Hospital and, between 1992 and 1995, he undertook medical oncology fellowship training at the National Cancer Institute in Bethesda, Maryland, USA. He is currently the Director and Distinguished Professor of the Graduate Institute of Oncology at NTU, the Director of the Department of Oncology at the NTU Hospital, and Director of Development and Planning at the new NTU Cancer Center.

    Dr Yang’s research focuses on lung cancer treatment and the mechanism of multidrug resistance to chemotherapy and targeted therapy. Dr Yang is a leader in lung cancer clinical studies, particularly in new drug development for lung cancer treatment. With other investigators he established EGFR TKIs as the front-line treatment for lung cancer patients with EGFR mutations (IPASS), and was the principle investigator of several studies that led to the global approval of second and third generation EGFR TKIs.

    He has published more than 200 papers in peer-reviewed scientific journals, such as the New England Journal of Medicine, The Lancet Oncology and Journal of Clinical Oncology, and served on the editorial board of Annals of Oncology and Lung Cancer. He is the current associate editor of Journal of Thoracic Oncology and Nature Scientific Reports.

    Dr Yang has been the recipient of many distinguished awards. He received the 2nd Kobayashi Foundation Cancer Research Award from the Asian Clinical Oncology Society in 2012, the Taiwan National Science Council award (2012–2015), the TECO award for biotechnology in 2015, and the research award from the Ministry of Science and Technology, Taiwan (2016-2018). He is currently serving on the Board of Directors for the IASLC until 2021.


    Dr Corey Langer

    University of Pennsylvania, Philadelphia, PA, USA

    Read full bio...

    Corey Langer, MD, is a Professor of Medicine at the University of Pennsylvania, the Clinical Director of Thoracic Oncology at the Abramson Cancer Center and Chair of the Medical Oncology Committee for the Radiation Therapy Oncology Group (RTOG), now NRG Oncology.

    Dr Langer received his medical degree from Boston University, MA and completed his internship and residency in medicine at the Graduate Hospital of the University of Pennsylvania in Philadelphia. He is board certified in internal medicine and in hematology/oncology.

    He is a Fellow of the American College of Physicians (ACP) and a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and the International Association for the Study of Lung Cancer (IASLC). He brings extensive clinical trial experience to research in the Cooperative Group system (Radiation Therapy Oncology Group [RTOG] and Eastern Cooperative Oncology Group [ECOG]), and is a core member of both the RTOG/NRG and ECOG Head and Neck Cancer and Thoracic Committees.

    Over the past 28 years he has led or co-led over 120 clinical trials in both small cell and non-small cell lung cancer, in the adjuvant, locally advanced and advanced disease setting, and at least 20 trials in head and neck cancer. His clinical research efforts include new drug combinations and special populations and, more recently, his focus has been on immuno-oncology trials. He is now very active in mentoring junior investigators as they launch their own clinical trials, and leads clinical research in thoracic malignancy as part of the Abramson Cancer Center’s Interdisciplinary Thoracic Oncology Program (ITOP). He has authored or co-authored over 170 peer-reviewed papers, primarily focussed on the treatment of smoking-related malignancies.

  • This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Imedex and Springer Healthcare. Imedex is accredited by the ACCME to provide continuing medical education for physicians.

    Imedex®, LLC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.